Summary: Serum concentrations of total cholesterol and lipoprotein cholesterol, of apolipoproteins AI and AII and of apolipoprotein AI in lipoprotein particles (Lp AI and Lp A) were determined in 43 patients with multiple myeloma.
Introduction
t . t . . , " · * _ , i which were inversely correlated with the monoclonal Most patients sufferiüg from multiple myelomatosis immunoglobulin level (4) . These two parameters apshow disturbances in serum cholesterol and lipopro-r pear to play central roles in corporeal cholesterol teins (l -3). Fiessinger et al. (3) described a decrease metabolism. The presence of several HDL classes has in -üpoproteins and less freqüently ßJipoproteins been confinned in many studies. In the studies of with hypocholesterolaemia in myeloma patient$ and Gofman et al. (5) HDL was separated by ultracentrisuggested that these decreases were associated with fugation based on density flotation into three subpoprogressive disease. We have observed thät the same pulations: HDL!, HDL 2 and HDL 3 . Without doubt, disease state is accompanied by decreases of HDL HDL 2 and HDL 3 are the major HDL populations cholesterol and apolipoprotein AI concentrations present in the plasma. As previously described, these subfractions could play distinct metabolic roles in pathological events (6, 7) or cellular cholesterol metabolism in vitro (8, 9) . Apolipoprotein AI exists in at least two different types of lipoprotein particles in human plasma (10, 11) . More than 50% of total apolipoprotein A I is associated with apolipoprotein AII (Lp A particles) while the rest exists in lipoproteins that contain no apolipoprotein All (Lp AI particles). These two populations of particles apparently may represent trwo metabolically distinct pools of apolipoprotein A I-containing lipoproteins (11) . The basis of the lower HDL cholesterol concentrations present in subjects with myelomatosis has not been previously elucidated. In view of the possibility of a distinct metabolic role for HDL-containing particles, it is of interest to determine which particle is involved in HDL pertubations in myeloma disease.
This study was undertaken to determine the level of cholesterol associated with LDL, HDL, HDL 2 and HDL 3 , the circulating mass of apolipoprotein AI and A II,\ and the AI concentrations of lipoprotein particles containing AI associated or unassociated with AII (AI (Lp A) and AI (Lp A I)) in patients suffering from myeloma. These studies increase our understanding of the pathological events which occur in cholesterol metabolism in myeloma.
Materials and Methods

Clinical populations
Studies were performed on 43 patients with multiple myeloma (28 females and 15 males). The diagnosis was based both on bone marrow histology and on the presence of monoclonal Ig or light chain gammopathy. The monoclonal gammopathies were IgG Kappa in 23 patients, IgG Lambda in 10 patients, IgA Lambda in 3 patients, IgA Kappa in 6 patients and Kappa light chains in one patient. The ages of the patients ranged between 40 and 60, except for 3 patients aged 75, 78, and 80 (10 patients between 40 and 50 years; 30 patients between 50 and 60 years).
On the basis of clinical examination and Standard biological Parameters of hepatic function (serum aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase and bilirubin), they were considered äs having normal liver function at the time of the blood sampling.
Since initial analysis indicated no differences between male and female patients, the data for the two groups were combined for the statistical analysis.
Sixty eight healthy nonnolipidaemic subjects were used äs controls for triacylglycerols and cholesterol, and thirty äs controls for plasma apolipoprotein AI of lipoprotein particles (A I (Lp A I) and A I (Lp A)) and for plasma apolipoproteins A I and A II. The age distribution of these two populations was in the same ränge äs the myeloma patients.
Blood samples were obtained by venipuncture from subjects who had fasted overnight. The blood was collected in 10 ml vacutainer tubes containing 0.5 ml of 5 mmol/1 EDTA, and centrifuged for 15 min at 2500 min-1 at 4 °C to separate cells from plasma. Plasma samples were kept frozen for more than one month, at -20 °C until analysis. In these conditions, no significant lipid or apolipoprotein modifications were observed.
Reagents
Manganese chloride and heparin sodium salt were purchased from Sigma Chemical Company; and dextran sulphate (Af r = 15000) was obtained from Sochifeo -3-5, rue Carnot, 92100 Boulogne-sur-Seine, France). All other reagents were of analytical grade.
Analytical methods
Plasma cholesterol and triacyglycerol (12, 13) concentrations were determined by enzymatic methods. LDL cholesterol was determined by a precipitation method (BioMerieux, Marcyl'Etoile 69260 Charbonnieres les Bains, France) äs was the cholesterol associated with HDL, HDL 2 and HDL 3 (12) .
Determination öf apolipoproteins A l and A II and of A I in lipoprotein particles (Lp A and Lp A I)
Apolipoprotein AI and A II were determined by tive enzyme-linked immunosorbent assay (14, 15) The quantitative determination of A I (Lp A) and AI (Lp AI) was performed using an automated enzyme-linked differential antibody immunosorbent technique, on microtitre plates. The procedure is described in detail elsewhere (16) .
Briefly, the method consisted of two assays: a) Measurement of total apolipoprotein AI by non^cpmpetitive enzyme-linked immunoassay (14) . Here, antibodies to apolipoprotein AI were coated on microtitre plates. After incubation with undelipidated plasma at various dilutioris, the total amount of apolipoprotein AI retained by these first antibodies was evaluated using peroxidase-labeled antibodies to apolipoprotein AI (A I (Lp A) + A I (Lp AI)).
b) For the measurement of AI (Lp A), the plate wells were coated with antibodies to apolipoprotein A II. After incubation with samples, only A I (Lp A) Jipoproteins were retained while A I (Lp AI) lipoproteins were removed in the washing process. The amount of apolipoproteins AI associated with AII was then evaluated by using again peroxidase labeled antibodies to apolipoprotein AI. Apolipoprotein AI unassociated with AII was evaluated by substracting the concentratioii of AI (Lp A) from total AI.
The assay of apolipoprotein A I associated with AII was linear over the ränge of 0.005 to 0.05 g/l. Within-and between^assäy CVs were 5.6 and 9.8% respectively (16) . LpA isolated from plasma from a normolipidaemic fasting subject was used äs Standard.
Statistical studies A preliminary statistical study based on an F lest indicates ä discrepancy between the variaiices of controls and myeloma populations. Comparisom of means was carried o\it by the Mann-Withney U-test. Spearmarfs test was used to identify significant (p < 0.05) relationships between parameters. the HDL cholesterol levels were significantly decreased (p < 0.001; tab. 1) in myeloma patients. The mean and SD of HDL chölesterol levels were l .07 ± 0.50 mmol/1 compared with 1.44 ± 0.36 mmol/1 in healthy subjects. This decrease affected particularly the HDL 3 subfraction (p < 0.001); the HDL 2 cholesterol was increased in myeloma (p < 0.001). This finding and the lower LDL cholesterol levels (p < 0.0001); 70% of cases) suggest that VLDL cholesterol must be elevated in this disease. Indeed approximate VLDL cholesterol concentrations (obtained by total cholesterol minus HDL cholesterol plus LDL cholesterol) were higher in myeloma patients (1.64 + 0.78 mmol/1 compared with 1.23 ± 0.49 mmol/1 in control group, p < 0.01):
Results
Consistent with this proposal is the qbservation that the myeloma patients have significantly higher plasma triacyglycerol levels (1.45 ± 0.6 mmol/1; p < 0.01) than controls (1.05 ± 0.4 mmol/1).
The plasma concentrations of both apolipoproteins AI and AII, and AI associated with AII (A I (Lp A) were significantly decreased in myeloma (p < 0.01; tab; 2). The apolipoprotein All levels (86% of cases, p < 0.0001) were more diminished than apolipoprotein AI (44% of cases, p < 0.001; tab. 2). This was consistent with the observation that, unlike AI (Lp A), the AI (Lp AI) levels were actually higher in myelomatosis (p < 0.05; tab. 2).
Plasma AI (Lp AI) and AI (Lp A) concentrations correlated positively with the cholesterol content of HDL, HDL 2 and HDL 3 (tab. 3). The proportion of these two types of particles varied with the ratio of HDL 2 and HDL 3 in the plasma (11) . In the same manner, the plasma AI (Lp AI) concentrations were 
Discussion
Our data showed significant decreases' of LDL, HDL and HDL 3 cholesterol, of apolipoproteins A I and AII and of A I (Lp A) in the plasma of patients with myelomatosis. In contrast with previous reports (l, 3), total plasma cholesterol was not «ignificantly affected by the disease.
Increased elimination rates of ß-lipoprotein and alipoprotein by the reticuloendothelial System following complex formation with the pathological globulin in the plasma might be the basis of the reduced plasma LDL-and HDL-cholesterol concentrations in our patients, äs suggested by Fiessinger et al. (3) . This hypothesis has never been confirmed in vivo and indeed identical lipid perturbations occur in the other haematological diseases such äs leukaemiä (17), a disease that does not show abnormal immunoglobulin synthesis. Bases & ATrafcöj^demonstrated increased phagocytic activity of the reticuloendothelial System in patients with chronic myeloproliferative disorders and hypocholesterolaemia (18) without complex' formation of lipoprotein with pathological globulin in the plasma. In the same disease, Ginsberg et al. (19) » observed reduced LDL cholesterol concentrations and suggested that these were associated with increased non receptor-mediated catabolism of LDL apolipoprotein B. If the reduced LDL-cholesterol in myeloma was due to increased activity of the reticuloendothelial System, why is an identical process not involved in HDL metabpjism? Indeed, we have observed an increase of cholesterol in HDL 2 without association with the tumofal mass expressed by the pathological immunoglobulin levels. These observations suggest that a more specific mechanisin is likely for the reduced LDL concentrations of patients with myeloma disease, bäsed öü increased LDL receptormediated uptake and degradation of LDL. Cells that have undergone malignant transformation are known to have altered cholesterol metabolism (20, 21) , and low LDL cholesterol levels in patients with acute leukaemia are the result of increased receptor-mediated LDL uptake and degradation by leukaemic cells .äs suggested by Vitols et al. (17) Elsewhere we cannot rule out the hypothesis that myeloma HDL have altered structure with an accompanying increase in their catäbolism. These structural modifications could result from Substitution of apolipoproteins AI and AII by another protein resulting from the disease. This phenomenon of one apolipoprotein displacing another has been shown by several authors (27, 28, 29) .
Preliminary results in our laboratory have shown the presence of serum amyloid A protein (SAA) in myeloma HDL. Parks et al. (30) have described, in a non-human primate, a displacement of AI, AII or C-apolipoproteins from HDL after induction with serum amyloid A protein.
We think that the presence of serum amyloid A protein could modulate the HDL surface and consequently facilitate the binding of HDL via specific sites to tumour cells. The decrease of apolipoproteins AI and AII, particularly of AI (Lp A) with relation to disease state could conceivably support this hypothesis. At least, these two apolipoproteins (A I and AII) are localized at the periphery of the lipoprotein particle (31) .
Studies are in progress in our laboratory to delineate the mechanism involved in the production of these perturbations in patients suffering from myeloma.
Our results suggest that determination of apolipoprotein AI, associated or unassociated with A II, provide Information that may be of value in assessing myeloma disease activity.
